At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MESO Mesoblast
Post-Mkt 09-04 19:17:35 EDT
17.32
+0.18
+1.05%
盘后17.32
+0.000.00%
18:52 EDT
High17.34Low17.03Vol93.50K
Open17.04D1 Closing17.14Amplitude1.78%
Mkt Cap2.25BTradable Cap1.46BTotal Shares129.69M
T/O1.61MT/O Rate0.11%Tradable Shares84.12M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX) and Mesoblast (MESO)
TIPRANKS  ·  09-04 20:10
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX) and Mesoblast (MESO)
Post-Approval Safety Risks Threaten Mesoblast’s Ryoncil Commercialization in Fragile Pediatric SR-aGVHD Market
TIPRANKS  ·  08-31
Post-Approval Safety Risks Threaten Mesoblast’s Ryoncil Commercialization in Fragile Pediatric SR-aGVHD Market
Mesoblast Earnings Call: RYONCIL Fuels Growth Story
TIPRANKS  ·  08-30
Mesoblast Earnings Call: RYONCIL Fuels Growth Story
Mesoblast Price Target Raised to $39.00/Share from $35.00 by Piper Sandler
Dow Jones  ·  08-28
Mesoblast Price Target Raised to $39.00/Share from $35.00 by Piper Sandler
Mesoblast FY EPS $(0.04) Misses $0.01 Estimate, Sales $120.250M Beat $66.000M Estimate
Benzinga Earnings  ·  08-27
Mesoblast FY EPS $(0.04) Misses $0.01 Estimate, Sales $120.250M Beat $66.000M Estimate
Reported Earlier, Mesoblast Reports FY2026 Total Revenue Of $120.3M Up From $17.2M, Net Loss Narrows 44% To $57.5M From $102.1M
Benzinga Earnings  ·  08-27
Reported Earlier, Mesoblast Reports FY2026 Total Revenue Of $120.3M Up From $17.2M, Net Loss Narrows 44% To $57.5M From $102.1M
Mesoblast Fiscal 2026 Loss Narrows; Revenue Up
MT Newswires Live  ·  08-27
Mesoblast Fiscal 2026 Loss Narrows; Revenue Up
Mesoblast Reports Substantial Revenue Growth to US$120M
GlobeNewswire  ·  08-27
Mesoblast Reports Substantial Revenue Growth to US$120M
Mesoblast Flags Risks Around 2026 Outlook and Stem Cell Strategy
TIPRANKS  ·  08-27
Mesoblast Flags Risks Around 2026 Outlook and Stem Cell Strategy
Mesoblast Files 2026 Form 20-F, Affirms Status as Well-Known Issuer
TIPRANKS  ·  08-27
Mesoblast Files 2026 Form 20-F, Affirms Status as Well-Known Issuer
Mesoblast Limited - There Can be no Assurance That We Will Ever Achieve or Maintain Profitability
THOMSON REUTERS  ·  08-27
Mesoblast Limited - There Can be no Assurance That We Will Ever Achieve or Maintain Profitability
Mesoblast Limited - Anticipate That We May Continue to Incur Significant Losses for Foreseeable Future
THOMSON REUTERS  ·  08-27
Mesoblast Limited - Anticipate That We May Continue to Incur Significant Losses for Foreseeable Future
Mesoblast Limited Expected to Post a Loss of 3 Cents a Share - Earnings Preview
Reuters  ·  08-25
Mesoblast Limited Expected to Post a Loss of 3 Cents a Share - Earnings Preview
Mesoblast Financial Results and Corporate Update Webcast
GlobeNewswire  ·  08-24
Mesoblast Financial Results and Corporate Update Webcast
Mesoblast Increases Director Philip Krause’s Equity-Based Incentives
TIPRANKS  ·  08-24
Mesoblast Increases Director Philip Krause’s Equity-Based Incentives
Mesoblast Stock Leads 3 Fast Growing ASX Picks With Strong Insider Ownership
Simply Wall St.  ·  08-23
Mesoblast Stock Leads 3 Fast Growing ASX Picks With Strong Insider Ownership
Mesoblast Stock Leads 3 Australian Growth Shares With Strong Earnings Expectations
Simply Wall St.  ·  08-23
Mesoblast Stock Leads 3 Australian Growth Shares With Strong Earnings Expectations
Mesoblast Stock Leads 3 High Growth Insider Owned ASX Shares To Watch
Simply Wall St.  ·  08-21
Mesoblast Stock Leads 3 High Growth Insider Owned ASX Shares To Watch
Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial
TIPRANKS  ·  08-17
Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial
Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain
GlobeNewswire  ·  08-17
Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain

Introduction

Company Name.
Mesoblast
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Issue price:
--